What is Xeris Biopharma Holdings, Inc.'s (XERS) StockRank?

MoatMap's StockRank for Xeris Biopharma Holdings, Inc. (XERS) is 60/100, with a Hold signal. This is a composite score combining Quality (59), Value (30), and Momentum (66) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Xeris Biopharma Holdings, Inc. have an economic moat?

Xeris Biopharma Holdings, Inc. (XERS) has a Quality factor score of 59/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Xeris Biopharma Holdings, Inc. a buy, hold, or sell?

MoatMap's current signal for Xeris Biopharma Holdings, Inc. (XERS) is Hold, based on a StockRank of 60/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Xeris Biopharma Holdings, Inc. in?

Xeris Biopharma Holdings, Inc. (XERS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

XERS

HoldPremium Grower

Xeris Biopharma Holdings, Inc. · Healthcare · United States · $1.5B · Avg Vol: $13M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

4.0%

D/E

18.9x

Dividend %

—

COMPANY DESCRIPTION

Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company leveraging its proprietary XeriSol and XeriJect formulation technologies to develop ready-to-use liquid injectables. These platforms eliminate the need for reconstitution, offering a distinct competitive advantage in patient convenience and adherence. The company operates as a niche player focused on endocrine, metabolic, and neurological conditions.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	110.2M	163.9M	203.1M	291.8M	38.3%	335.4M	387.5M	480.7M	28.3%
EPS	-0.70	-0.45	-0.37	0.00	—	-0.10	—	—	—
Shares	136.3M	138.1M	149.4M	166.2M	+22.0%	182.3M	—	—	—
Debt	198.1M	229.2M	271.4M	258.1M	9.2%	289.4M	—	—	—
Equity	45.2M	-6.8M	-29.6M	13.7M	-32.8%	—	—	—	—
Op CF	-102.9M	-47.0M	-37.0M	28.6M	—	56.6M	—	—	—
Inv CF	34.5M	-6.0M	4.9M	-0.7M	—	—	—	—	—
Fin CF	127.5M	-1.6M	36.2M	11.4M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+0.3%

SMA 50SMA 200

$8.40

RSI (14)

30.6

52W High

$10.08

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

4.0%53.6

ROE

4.0%25.0

GP/Assets

75.7%95.2

Op. Margin

5.6%53.7

FCF/Assets

14.5%93.1

Piotroski

894.2

Int. Cover

0.4x37.0

D/E Ratio

18.85x0.7

Current Ratio

1.45x25.1

Value

P/E (TTM)

—N/A

EV/EBITDA

35.3x17.9

P/FCF

27.8x49.4

P/B

-152.3x25.0

P/S

4.6x43.6

Div Yield

—N/A

Momentum

52W High %

83%73.7

RS 6M

31%85.6

SMA 50/200

1.19x87.4

EPS Rev 4W

-0.6%26.1

EPS Rev 12W

-1.3%29.5

EPS Improve

+490%95.7

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.5B

P/E (Forward)

21.9x

Gross Margin

86.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XERS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
XERS	Xeris Biopharma Holdings, Inc.(you)	$1.5B	60	Hold
PAHC	Phibro Animal Health Corporation	$1.5B	74	Buy
ETON	Eton Pharmaceuticals, Inc.	$1.7B	72	Buy
PBH	Prestige Consumer Healthcare Inc.	$2.5B	67	Buy
CURA.TO	Curaleaf Holdings, Inc.	$2.6B	48	Hold
EOLS	Evolus, Inc.	$587M	55	Hold
COLL	Collegium Pharmaceutical, Inc.	$786M	72	Buy
SUPN	Supernus Pharmaceuticals, Inc.	$2.5B	43	Hold
LQDA	Liquidia Corporation	$6.1B	64	Hold
HROW	Harrow, Inc.	$1.5B	29	Sell

Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%

Xeris Biopharma Holdings, Inc. (XERS): Stock Score Summary

Xeris Biopharma Holdings, Inc. (XERS) has a MoatMap StockRank of 60/100 based on Quality (59/100), Value (30/100), and Momentum (66/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$8.40
Market Cap	$1.5B
P/E (Forward)	21.87
Price/Book	-152.32
Return on Equity	4.0%
Return on Invested Capital	4.0%
Debt/Equity	18.85x
Gross Margin	86.6%
Operating Margin	5.6%
Revenue Growth	28.7%
Free Cash Flow	$56M

Xeris Biopharma Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Xeris Biopharma Holdings, Inc.’s (XERS) StockRank?: MoatMap’s StockRank for Xeris Biopharma Holdings, Inc. (XERS) is 60/100, with a Hold signal. It is a composite of Quality (59), Value (30), and Momentum (66) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Xeris Biopharma Holdings, Inc. have an economic moat?: Xeris Biopharma Holdings, Inc. (XERS) has a Quality factor score of 59/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Xeris Biopharma Holdings, Inc. a buy, hold, or sell?: MoatMap’s current signal for Xeris Biopharma Holdings, Inc. (XERS) is Hold, based on a StockRank of 60/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Xeris Biopharma Holdings, Inc. in?: Xeris Biopharma Holdings, Inc. (XERS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).